Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10428194.2024.2410942 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cost-effectiveness of Enasidenib versus conventional care for older patients with mutant refractory/relapsed AML.
Leuk Lymphoma
November 2024
Section of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
In the randomized phase III IDHENTIFY trial, the IDH2 inhibitor enasidenib (ENA) showed improvement in event-free but not overall survival compared with conventional care regimens (CCR) among patients with relapsed/refractory (R/R), -mutant AML. We constructed a partitioned survival model to evaluate the cost-effectiveness of enasidenib for the treatment of older patients with R/R, and -mutant AML. In the base-case scenario, ENA exhibited an incremental effectiveness of 0.
View Article and Find Full Text PDFA review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDS.
Expert Rev Hematol
November 2024
Hematology Section, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Article Synopsis
- It highlights the different treatment combinations available, including monotherapy and pairings like ivosidenib with azacitidine, while exploring their effectiveness and survival benefits.
- Lastly, it points out ongoing uncertainties in treatment choices and the need for more randomized trials to clarify the best approaches, especially after transplantation and in combination with other therapies.
Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia.
Bone Marrow Transplant
October 2024
Fralin Biomedical Research Institute, Virginia Tech FBRI Cancer Research Center, Washington, DC, USA.
Routine genetic profiling of acute myeloid leukemia (AML) at initial diagnosis has allowed subgroup specific prognostication, drug development, and clinical management strategies. The optimal approach for treatment response assessment for AML subgroups has not yet however been determined. A nationwide cohort of 257 adult patients in first remission (CR1) from AML associated with an IDH2 mutation (IDH2m) undergoing allogeneic transplant during the period 2013-2019 in the United States had rates of relapse and survival three years after transplantation of 24% and 71%, respectively.
View Article and Find Full Text PDFMaintenance Therapy in Acute Myeloid Leukemia.
Am J Clin Oncol
September 2024
Chief Division of Hematology/Oncology, Anne Arundel Medical Center, George Washington University, Annapolis, MD.
Article Synopsis
- Acute myeloid leukemia (AML) has high relapse rates after initial chemotherapy, prompting the need for effective maintenance therapies, especially for high-risk patients.
- * Current treatments include hypomethylating agents like azacitidine and decitabine, which have shown benefits for older patients, alongside targeted therapies such as FLT3 inhibitors for specific mutations.
- * Despite advances, the effectiveness of maintenance chemotherapy is uncertain, highlighting the importance of ongoing research and the potential of personalized treatment approaches.*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!